ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

There is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients
with cognitive impairment, especially when coexisting with Alzheimer's disease (AD) …

Synucleinopathies are clinically and pathologically heterogeneous disorders characterized
by pathologic aggregates of α-synuclein in neurons and glia, in the form of Lewy bodies …

Investigations of apolipoprotein E (APOE) gene, the major genetic risk modifier for
Alzheimer's disease (AD), have yielded significant insights into the pathogenic mechanism …

TYROBP (also known as DAP12 or KARAP) is a transmembrane adaptor protein initially
described as a receptor-activating subunit component of natural killer (NK) cells. TYROBP is …

Alzheimer's disease (AD) is pathologically defined by the presence of fibrillar amyloid β (Aβ)
peptide in extracellular senile plaques and tau filaments in intracellular neurofibrillary …

Transactive response DNA binding protein of 43 kDa (TDP-43) is an intranuclear protein
encoded by the TARDBP gene that is involved in RNA splicing, trafficking, stabilization, and …

Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

Parkinson's disease (PD) is the second most common neurodegenerative disorder and the
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …